Abstract
An 82-year-old man, who was diagnosed in 2002 with an oncocytic (Hürthle cell) thyroid carcinoma, was initially treated by local surgery and was refractory to radioiodine treatment. The patient had successive secondary recurrences from 2006 onwards. Metastases were suspected due to an elevation of thyroglobulin in serum. Hypermetabolic nodules were targeted using FDG PET as well as CT-guided radiofrequency ablations. Thyroglobulin levels decreased following each procedure. 10 years later, tolerance and efficacy are excellent; 23 lung metastases have been treated during 11 sessions without current relapse. Respiratory function and quality of life are not altered. This report illustrates how radiofrequency ablation can be efficiently integrated into the long-term management of poorly aggressive oligometastatic cancer, in combination with other local and/or systemic therapies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
de Baère T, Palussière J, Aupérin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240(2):587–96.
de Baère T, Aupérin A, Palussiére J, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987–91.
de Baère T. Lung tumor radiofrequency ablation: where do we stand? Cardiovasc Intervent Radiol. 2011;34(2):241–51.
Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013;119(3):504–11.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
Bonichon F, Palussière J, Godbert Y, et al. Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2013;40(12):1817–27.
Tochio M, Takaki H, Yamakado K, et al. A case report of 20 lung radiofrequency ablation sessions for 50 lung metastases from parathyroid carcinoma causing hyperparathyroidism. Cardiovasc Intervent Radiol. 2010;33(3):657–9.
Owen D, Oliver KR, Garces YI, et al. Outcomes of Stereotactic Body Radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiati Oncol. 2015;18(10):43.
Dupuy DE, Fernando HC, Putnam JB, et al. Radiofrequency ablations of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Allianc) trial. Cancer. 2015;121(19):3491–8.
Tada A, Hiraki T, Iguchi T, et al. Influence of radiofrequency ablation of lung cancer on pulmonary function. Cardiovasc Intervent Radiol. 2012;35(4):860–7.
Acknowledgments
The authors would like to thank Dr. Ravi Nookala of Institut Bergonié and Camille Lacadée for medical writing services.
Funding information
No funding was received for this report.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
For this type of study, formal consent is not required.
Informed consent
Informed consent was obtained from the patient.
Rights and permissions
About this article
Cite this article
Crombé, A., Buy, X., Godbert, Y. et al. 23 Lung Metastases Treated by Radiofrequency Ablation Over 10 Years in a Single Patient: Successful Oncological Outcome of a Metastatic Cancer Without Altered Respiratory Function. Cardiovasc Intervent Radiol 39, 1779–1784 (2016). https://doi.org/10.1007/s00270-016-1445-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-016-1445-8